GoodRx (NASDAQ:GDRX) Shares Gap Up – Time to Buy?

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $4.76, but opened at $4.92. GoodRx shares last traded at $4.86, with a volume of 39,870 shares traded.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. UBS Group dropped their target price on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research report on Friday, August 9th. Raymond James upgraded GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target on the stock in a research report on Friday, August 9th. Citigroup dropped their target price on GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price target on shares of GoodRx in a research report on Friday, August 16th. Finally, Barclays reduced their target price on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $8.86.

GoodRx Trading Down 0.8 %

The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The business has a fifty day moving average of $6.02 and a 200-day moving average of $7.26.

Insiders Place Their Bets

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 4.17% of the company’s stock.

Institutional Investors Weigh In On GoodRx

Several hedge funds and other institutional investors have recently modified their holdings of GDRX. Cornercap Investment Counsel Inc. lifted its stake in GoodRx by 1.7% during the second quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock worth $587,000 after purchasing an additional 1,266 shares during the period. California State Teachers Retirement System boosted its stake in GoodRx by 5.1% in the 1st quarter. California State Teachers Retirement System now owns 70,912 shares of the company’s stock valued at $503,000 after buying an additional 3,444 shares in the last quarter. nVerses Capital LLC bought a new stake in GoodRx in the third quarter valued at $33,000. Plato Investment Management Ltd acquired a new position in GoodRx during the second quarter worth $43,000. Finally, XTX Topco Ltd lifted its holdings in shares of GoodRx by 42.4% during the second quarter. XTX Topco Ltd now owns 29,560 shares of the company’s stock valued at $231,000 after acquiring an additional 8,801 shares during the period. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.